Therapy News and Research

RSS

HAART saves 2 million life years

The total impact of HIV treatment in the US has been evaluated for the first time. Dr. Rochelle Walensky, ( Harvard Medical School in Boston), speaking at the 12th Annual Retrovirus Conference, quoted from research which estimated the survival benefits of highly active antiretroviral therapy (HAART) and opportunistic infection prophylaxis in the US from 1989 to 2003.

2 Mar 2005

$Vitamin B12 after stroke reduces risk of hip fracture$

Vitamin B12 after stroke reduces risk of hip fracture

Patients who took folic acid and vitamin B12 after their stroke had a reduced risk of hip fracture compared to patients who took placebo, according to an article in the March 2 issue of JAMA.

1 Mar 2005

Artery clearing device does not provide benefit for heart attack patients undergoing artery-opening interventions

Use of a device and system to clear dislodged "debris" during percutaneous interventions to open a blocked artery following a heart attack does not appear to be clinically beneficial, according to a study in the March 2 issue of JAMA.

1 Mar 2005

alpha-defensin-1, a protein found in immune cells, can control HIV infection

Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.

1 Mar 2005

Researchers can now predict who will benefit from cerclage

Doctors treating pregnant women with threatened preterm birth sometimes sew the cervix closed, a procedure known as cerclage. Despite this traditional intervention, many women still lose the pregnancy.

1 Mar 2005

Study describes the first known mutation to occur in lung cancer patients who have never smoked

Lung cancer patients who have never smoked are more likely than smokers to harbor one of two genetic mutations that researchers at UT Southwestern Medical Center have now linked to the disease.

1 Mar 2005

CPAP therapy helps control glucose levels among patients with Type II diabetes and sleep apnea

Patients with Type II diabetes who also suffer from obstructive sleep apnea can lower their glucose levels by receiving the most common sleep apnea therapy, a new study has found.

1 Mar 2005

Nature’s most sophisticated biological weapon

Nature’s most sophisticated biological weapon, snake venom, largely evolved from bits of body parts a Melbourne researcher has found.

1 Mar 2005

Scientists re-produce the human body's own cancer-killing cells through gene therapy

New hope to cancer sufferers comes from research by South Korean scientists who have found a way to re- produce the human body's own cancer-killing cells through gene therapy.

1 Mar 2005

Stop smoking services encourage more GPs to help smokers quit

Clinics to help people stop smoking have led to an increased number of GPs recording whether patients smoke and referring them for assistance to quit – according to a new report.

1 Mar 2005

Genetic link to kidney damage after heart surgery

Specific variants of genes involved in inflammation and blood vessel constriction are strongly associated with kidney damage in patients undergoing major heart surgery, researchers at Duke University Medical Center have found.

1 Mar 2005

Celebrex provides a two pronged attack against prostate cancer

Celecoxib, a selective COX-2 inhibitor with promising anti-cancer properties, has now been found to attack prostate cancer cells in a second way that differs from Vioxx (rofecoxib), another anti-inflammatory drug that also inhibits COX-2.

1 Mar 2005

New cancer drug Avastin keeps cancer under control

Data published for the first time today in the leading Journal of Clinical Oncology showed that the unique new cancer drug Avastin keeps cancer under control for a significantly longer duration, even when used in a group of elderly patients with advanced colorectal cancer who are too sick to tolerate traditional aggressive chemotherapy.

1 Mar 2005

OPAL, major discovery in the fight against AIDS

Australian researchers have made a major discovery in the fight against AIDS, with the development of a novel, simple and safe technique for boosting the body’s immune response to deadly viruses like HIV, which is even effective against drug resistant forms of the disease.

1 Mar 2005

Kidney dysfunction in HIV patients can be detected earlier

Tracking the subtle kidney damage that can lead to chronic kidney disease in HIV patients is increasingly important as people survive longer and may have an increased risk of renal dysfunction as a result of their disease, therapy-related damage, or co-morbid conditions such as diabetes mellitus and hypertension.

28 Feb 2005

VIRxSYS novel HIV gene therapy yields exciting results

VIRxSYS Corporation reports unexpected and unprecedented findings in its ongoing Phase I clinical trial of its VRX496 therapy in patients with HIV.

28 Feb 2005

Encouraging results in wet age-related macular degeneration study

Novadaq Technologies has announced that Dr. Giovanni Staurenghi, (Associate Professor of Ophthalmology, Department of Otorhinolaryngological and Ophthalmological Science University of Milan, Italy), reported preliminary data on 24-patients in an on-going study using the Company's proprietary technology to treat wet Age-Related Macular Degeneration (AMD).

28 Feb 2005

Unique study of the use of deep brain stimulation

Canadian researchers have seen promising results from a unique study of the use of deep brain stimulation (DBS), in severely depressed patients resistant to standard treatments.

28 Feb 2005

Intravenous vitamin D appears to significantly improve the survival of patients on dialysis

The administration of intravenous vitamin D appears to significantly improve the survival of patients on dialysis, according to a study that will be published in the April Journal of the American Society of Nephrology.

28 Feb 2005

Study first to document increase risk of herpes infection due to oral sex, particularly in young women

The first clinical study to document risk of acquiring herpes simplex virus type 1 infection based on sexual activity has linked oral sex and vaginal intercourse with a demonstrably higher rate of infection, particularly in young women, researchers from the University of Pittsburgh report in the February issue of Sexually Transmitted Diseases, the journal of the American Sexually Transmitted Diseases Association.

28 Feb 2005